Studies say that the vaccine, AZD1222 was able to produce a dual response in volunteers aged between 18-55:

“Now what this vaccine does particularly well is triggered both arms of the immune system in addition to neutralizing antibodies which other vaccines do, we also see a very strong T-cell response,” says Professor Adrian Hill, Director of the Jenner Institute, Oxford University.

Richard Horton, the editor of the UK-based science journal ‘The Lancet’ also noted that “the vaccine is safe, well-tolerated, and immunogenic.”

While Oxford researchers are still proceeding ahead with phase III of their trials, the largest and the most critical one, the news of the vaccine’s early-stage results sound nothing but good bells, not just for the world but for India and there is more than one reason for the same: